Licensing status

Publication and contact information


Dermal ulcers

Wiskott-Aldrich syndrome-like (WASL; N-WASP)

In vitro and mouse studies suggest inhibiting the interaction between mycolactone and N-WASP could help treat Buruli ulcers. In cultured epithelial cells, wiskostatin inhibited the activation of N-WASP family proteins and the impairment of epithelial cell adhesion and direction sensing caused by mycolactone, the Mycobacterium ulcerans secretion that causes Buruli ulcers. In mice injected with mycolactone in the ear, wiskostatin prevented epithelial damage. Next steps could include testing wiskostatin in mouse models for M. ulcerans infection and developing additional N-WASP inhibitors.
Wiskostatin is a chemical reagent.

SciBX 6(12); doi:10.1038/scibx.2013.287
Published online March 28, 2013

Patent and licensing status unavailable

Guenin-Macé, L. et al. J. Clin. Invest.; published online March 15, 2013;
Contact: Caroline Demangel, Pasteur Institute, Paris, France